Add once-daily Kerendia to your patients’ current regimen

 

10 mg if:

  • Serum potassium is ≤4.8 mmol/L, or >4.8 to 5.0 mmol/L with additional monitoring*

and

  • eGFR is ≥25 to <60 mL/min/1.73 m2
     

 

20 mg if:

  • Serum potassium is ≤4.8 mmol/L, or >4.8 to 5.0 mmol/L with additional monitoring*

and

  • eGFR is ≥60 mL/min/1.73 m2
     


Check serum potassium
and eGFR 4 weeks after:
 

 

  • initiation
  • restart
  • increase in dose

and routinely afterwards

 

Serum potassium
(mmol/L)

10 mg

20 mg

≤4.8

Increase to 20 mg if eGFR has not
decreased >30% compared with the
prior measurement

Maintain dose

>4.8 to 5.5

Maintain dose

Maintain dose

>5.5

Withhold Kerendia and restart at 10 mg when serum
potassium decreases to ≤5.0 mmol/L. Remeasure serum
potassium and eGFR 4 weeks after restart

Withhold Kerendia and restart at 10 mg when serum
potassium decreases to ≤5.0 mmol/L. Remeasure serum
potassium and eGFR 4 weeks after restart

*If serum potassium is >4.8 to 5.0 mmol/L, initiation of Kerendia treatment may be considered with additional serum potassium monitoring within the first 4 weeks based on patient characteristics and serum potassium levels.

 

  • Continue to routinely monitor serum potassium and eGFR, and titrate Kerendia as needed
  • Patients can continue to take commonly prescribed medications including antidiabetic and antihypertensive therapies while on Kerendia
  • Patients with eGFR ≥15 mL/min/1.73 m2 can continue Kerendia treatment with dose adjustment based on serum potassium†

Potassium management

  • There were no dietary restrictions regarding potassium for patients in the FIDELIO-DKD trial and the FIGARO-DKD trial
  • Potassium-lowering therapies (such as sodium polystyrene sulfonate, calcium polystyrene sulfonate, and potassium-binding agents) were allowed in both trials
Discover helpful resources for your patients